Navigation Links
Drug, Pacemaker Fight Irregular Heartbeat
Date:9/5/2007

Studies suggest new weapons against dangerous atrial fibrillation

WEDNESDAY, Sept. 5 (HealthDay News) -- Cardiac researchers say a new drug may help treat the abnormal heartbeat called atrial fibrillation.

The drug, dronedarone, is not yet approved by the U.S. Food and Drug Administration but has proven effective in two major trials, with fewer side effects than existing medications, according to a report in the Sept. 6 issue of the New England Journal of Medicine.

And in the same issue of the journal, researchers say a special pacemaker can help prevent the development of atrial fibrillation in people with sinus-node disease -- a dysfunction of the cardiac region controlling heartbeat.

The American Heart Association estimates that 2.2 million Americans, many of them elderly, have atrial fibrillation, in which the two upper chambers of the heart lose their regular rhythm.

The condition increases the risk of dangerous clots forming as blood pools in the heart. Atrial fibrillation is treated with drugs that prevent clot formation and also with medications that restore the heart's normal rhythm.

The two trials -- which were funded by Sanofi-Aventis, the maker of dronedarone -- included more than 1,200 participants with atrial fibrillation.

In one European trial, the heartbeat remained normal for an average of 96 days in those getting dronedarone, compared to 41 days in those getting a placebo. In the other trial, conducted in the United States and several other countries, the heartbeat remained normal for an average of 158 days for those getting dronaderone and 59 days in those getting placebo.

Most important, the incidence of dangerous side effects -- such as occur with an approved drug, amiodarone -- was low in the dronedarone trial, said lead researcher Dr. Bramah N. Singh, a professor of medicine at the University of California at Los Angeles. Amiodarone can affect t
'/>"/>

Copyright©2007 ScoutNews,LLC.
All rights reserved

2

GOOD

Page: 1 2 3

Related medicine news :

1. FDA Approves New HIV Drug, Viread
2. FDA Approves New Arthritis Drug, Bextra
3. New Drug, Pleconaril speeds recovery from common cold
4. Multiple Sclerosis drug, Tysabri banned due to neurological disorders
5. Herceptin Not A ‘Wonder’ Drug, Says The Lanct
6. NGO Files Pre-Grant Opposition Against Anti-HIV Drug, Combivir
7. Life-Saving Cancer Drug, Herceptin Will be Available Free for Breast Cancer Patients in Wales
8. Diabetes Drug, Exenatide, Good For Blood Sugar Levels and Weight Loss
9. FDA Gives Approval for Skin Cancer Drug, Zolinza
10. Was the Warning of a Severe Reaction To a Drug, Overlooked?
11. Anti-Craving Drug, Naltrexone Helps Women Quit Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... By studying one of the most successful ... of successful strategies in his article What We Can ... Study. , The inspirational brand Gollan refers to is ... an impressive 62 million followers (and rising). , The ... Facebook Pages earlier this year. The Facebook data tracking publication ...
(Date:6/18/2013)... Lesbian, Gay, Bisexual and Transgender (LGBT) Pride ... sexual minority youth are still at greater ... according to the Suicide Prevention Resource Center. ... recently published recommendation to improve psychologists, treatment ... improve psychological functioning and reduce depression and ...
(Date:6/18/2013)... system using a person,s DNA was announced as ... London Startup Competition, Europe,s largest technology conference. ... on University of Bristol research by its founders, ... Professor of Bioinformatics in the University,s Department of ... to be one of 16 finalists in the ...
(Date:6/18/2013)... AZ (PRWEB) June 18, 2013 ... Stevie® Award in the Company of the Year category ... last night. , The American Business Awards are the ... the U.S.A. are eligible to submit nominations – public ... , Nicknamed the Stevies for the Greek word for ...
(Date:6/18/2013)... cough outbreaks are more likely to die prematurely even ... in Sweden has found. Women had a 20% higher ... 40%. Women also suffered more complications during and after ... as infant death within the first month of life. ... patients with exposure to whooping cough in childhood, particularly ...
Breaking Medicine News(10 mins):Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 2Health News:Casey Gollan Shows What We Can Learn From One of the Best Facebook Pages There Is 3Health News:Sexual minority youth need specialized treatment from therapists 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 2Health News:CyraCom International, Inc. Honored as a Gold Stevie® Award Winner in 2013 American Business Awards 3
... MADISON, N.J., Nov. 8 Wyeth (NYSE: WYE ... Suisse First Boston,Healthcare Conference on Tuesday, November 13, 2007 ... Joseph M. Mahady, Senior Vice President,Wyeth and President, Wyeth ... live for investors at, http://www.wyeth.com and available for ...
... Mutual and Ohio Farm Bureau,Federation (OFBF) have announced ... to OFBF,s more than 230,000 members. Effective ... access to,Medical Mutual,s SuperMed provider network, the most ... providers in Ohio. Medical,Mutual and OFBF have worked ...
... for injury, study finds , THURSDAY, Nov. 8 (HealthDay ... medications may cut their risk for fracture, Canadian researchers ... there,s an increased risk of additional fractures, other health ... in osteoporosis patients are hip, spine, and wrist fractures. ...
... Focusing on his experience as a physician in ... Harris, MD, FACP, president-elect of the American College of ... Committee Subcommittee on Regulations, Healthcare and Trade. , ... financial struggles that Medicare payments to physicians played on ...
... Va. (Nov. 8, 2007) Virginia Commonwealth University researchers ... that play a major role in clotting disorders, which ... the lungs and those localized deep in the body ... occur when the effect of thrombin, a protein involved ...
... Nov. 8 Pathwork Diagnostics, a,genomics-based diagnostics company ... Origin Test is the focus of two studies ... Meeting of the Association,for Molecular Pathology (November 7-10, ... help determine a tumor,s origin so that,tissue-specific management ...
Cached Medicine News:Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 2Health News:Ohio Farm Bureau Health Plan Awarded to Medical Mutual of Ohio 3Health News:Sticking With Meds Lowers Elderly Fracture Risk 2Health News:Looming Medicare cuts will disproportionately hurt physicians in small practices 2Health News:Researchers identify molecules with interesting anti-clotting properties 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 2Health News:Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics' Tissue of Origin Test 3
(Date:6/18/2013)...   Polymer Technology Systems, Inc. (PTS) ... to integrate the CardioChek ® PA ... health systems across the country. The CardioChek PA ... through Hanson Medical Systems , offers immediate, ... cholesterol, triglycerides, and glucose. (Logo: ...
(Date:6/17/2013)... Quebec , June 17, 2013 Valeant Pharmaceuticals ... announced today that it has filed a preliminary prospectus supplement ... has today made a similar filing with securities regulatory authorities ... in connection with a public offering of its common ... "Offering"). The Company will also grant to the ...
(Date:6/17/2013)... , June 17, 2013  A little known drug industry ... scrutiny by the U.S. Supreme Court – and a ruling ... could not have come at a better time for New ... from the Rx industry tactic are all too apparent in ... 50+ New Yorkers, state residents are in a near Rx ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 2Valeant Pharmaceuticals Announces Public Offering Of Common Shares 3Valeant Pharmaceuticals Announces Public Offering Of Common Shares 4Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 2Supreme Court Ruling on Rx Industry's Pay-to-Delay-Generics Good News for NY Consumers 3
... (NYSE Amex: ANX ) today announced the closing ... of its common stock and warrants exercisable for up to ...  The securities sold in the offering were sold in a ... 0.5 of a share at a price to the public ...
... 16, 2011 An analysis of the TRITON-TIMI 38 ... American Heart Association (AHA) Scientific Sessions meeting examined the ... death, myocardial infarction [MI] and stroke) compared to clopidogrel ... in acute coronary syndrome (ACS) patients with ST-segment elevation ...
Cached Medicine Technology:ADVENTRX Announces Closing of Public Offering 2ADVENTRX Announces Closing of Public Offering 3New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 2New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 3New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 4New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 5New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 6New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 7New Analysis of Data Presented at AHA Regarding Effect of Effient® (Prasugrel) on Cardiovascular Events in STEMI Patients According to Timing of PCI 8
The D.O.R.C. Silicone Oil is an ultra purified silicone oil which leads a maximum interfacial tension and minimizes interactions between tissues, cells and endo-tamponades media. (Sterile, 10 ml.)...
Eftiar® offers the vitreoretinal surgeon a temporary tamponade for efficient re-attachment of the retina, release of subretinal fluid, dissection of fibro-vascular proliferation and controlling r...
Clear Vinyl Urethral Catheters (100% Latex Free)...
100% Silicone Foley Catheter Kits 2-Way...
Medicine Products: